Suppr超能文献

雌激素下调剂氟维司群增强氟嘧啶类药物在雌激素反应性 MCF-7 人乳腺癌细胞中的抗肿瘤活性。

Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells.

机构信息

Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan

Pharmacology Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.

出版信息

In Vivo. 2019 Sep-Oct;33(5):1439-1445. doi: 10.21873/invivo.11622.

Abstract

BACKGROUND

Endocrine therapy is clinically administered in hormone-responsive breast cancer. Combinations of fluoropyrimidine S-1 and an aromatase inhibitor or anti-estrogen are considered beneficial in Japan. Herein we assessed new combinations of S-1 and fulvestrant.

PATIENTS AND METHODS

Cytotoxicity of fulvestrant and 5-fluorouracil (5-FU) was assessed in hormone-responsive (MCF-7) and non-responsive (MDA-MB-231) breast cancer cell cultures. Fulvestrant and S-1 were evaluated for antitumor activity in mice and their effects on estrogen receptor (ER)-α and progesterone receptor (PgR) levels in MCF-7 xenografts using immunohistochemical methods.

RESULTS

Fulvestrant inhibited growth of MCF-7, but not of MDA-MB-231 xenografts. Combinations of 5-FU and fulvestrant were superior to monotherapy in vitro. In vivo antitumor activity of S-1/fulvestrant combination therapy was significantly (p<0.05) enhanced compared to that of both monotherapies. Fulvestrant partially down-regulated expression of ERα and PgR, but in combination with S-1, it almost completely blocked their expression.

CONCLUSION

Chemo-endocrine combination therapy using S-1 and fulvestrant is beneficial in estrogen-responsive breast cancer.

摘要

背景

内分泌疗法在激素反应性乳腺癌的临床治疗中得到应用。氟嘧啶 S-1 与芳香酶抑制剂或抗雌激素联合应用被认为在日本是有益的。在此,我们评估了 S-1 和氟维司群的新组合。

患者和方法

在激素反应性(MCF-7)和非反应性(MDA-MB-231)乳腺癌细胞培养物中评估氟维司群和 5-氟尿嘧啶(5-FU)的细胞毒性。用免疫组织化学方法评估氟维司群和 S-1 在 MCF-7 异种移植瘤中的抗肿瘤活性及其对雌激素受体(ER)-α和孕激素受体(PgR)水平的影响。

结果

氟维司群抑制 MCF-7 的生长,但不抑制 MDA-MB-231 异种移植瘤的生长。5-FU 和氟维司群联合治疗在体外优于单药治疗。与单药治疗相比,S-1/氟维司群联合治疗的体内抗肿瘤活性显著增强(p<0.05)。氟维司群部分下调 ERα 和 PgR 的表达,但与 S-1 联合使用时,几乎完全阻断其表达。

结论

使用 S-1 和氟维司群的化疗-内分泌联合治疗对雌激素反应性乳腺癌有益。

相似文献

3
Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
Oncol Rep. 2018 Mar;39(3):1215-1226. doi: 10.3892/or.2018.6212. Epub 2018 Jan 11.
6
Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
Clin Cancer Res. 2019 Jun 15;25(12):3658-3672. doi: 10.1158/1078-0432.CCR-18-2434. Epub 2019 Mar 4.
8
Identification of estrogen receptor down-regulators for endocrine resistant breast cancer.
J Steroid Biochem Mol Biol. 2022 Nov;224:106162. doi: 10.1016/j.jsbmb.2022.106162. Epub 2022 Aug 4.
10
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
J Steroid Biochem Mol Biol. 2019 Oct;193:105415. doi: 10.1016/j.jsbmb.2019.105415. Epub 2019 Jun 19.

引用本文的文献

1
Synthetic Ionizable Colloidal Drug Aggregates Enable Endosomal Disruption.
Adv Sci (Weinh). 2023 May;10(13):e2300311. doi: 10.1002/advs.202300311. Epub 2023 Mar 11.
3
Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
PLoS One. 2021 Jun 8;16(6):e0252822. doi: 10.1371/journal.pone.0252822. eCollection 2021.

本文引用的文献

2
Cancer statistics, 2018.
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
8
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
J Clin Oncol. 2016 Sep 1;34(25):3069-103. doi: 10.1200/JCO.2016.67.1487. Epub 2016 May 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验